Effect of early treatment of prostate cancer with the 5α-reductase inhibitor turosteride in dunning R3327 prostatic carcinoma in rats

Prostate

Volumn 35, Issue 4, 1998, Pages 237-242

  Zaccheo, Tiziana ^a   Giudici, Donata ^a   Di Salle, Enrico ^a  

^a PFIZER INC   (United States)

Author keywords

Experimental model; FCE 26073; Tumor prevention

Indexed keywords

STEROID 5ALPHA REDUCTASE INHIBITOR; TUROSTERIDE;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER PREVENTION; CASTRATION; CONTROLLED STUDY; DRUG EFFECT; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTATE CANCER; RAT;

ADMINISTRATION, ORAL; ANIMALS; CELL LINE; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FINASTERIDE; MALE; ORCHIECTOMY; ORGAN SIZE; PROSTATE; PROSTATIC NEOPLASMS; RATS; TESTOSTERONE 5-ALPHA-REDUCTASE; TIME FACTORS;

EID: 0032102969     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19980601)35:4<237::AID-PROS1>3.0.CO;2-D     Document Type: Article

References (20)

1. Ford LG, Brawley OW, Perlman JA, Nayfield SG, Johnson KA, Kramer BS: The potential for hormonal prevention trials. Cancer 1994;74:2726-2733.
2. Hammond GL: Endogenous steroid levels in the human prostate from birth to old age: A comparison of normal and diseased tissues. J Endocrinol 1978;78:7-19.
3. Klein H, Bressel M, Kastendieck H, Voigt KD: Quantitative assessment of endogenous testicular and adrenal sex steroids and of steroid metabolizing enzymes in untreated human prostatic cancerous tissue. J Steroid Biochem 1988;30:119-130.
4. Liao S, Liang T, Tymoczko JL: Structural recognition in interactions of androgens and receptor proteins and in their association with nuclear components. J Steroid Biochem 1972;3:401-407.
5. di Salle E, Briatico G, Giudici D, Ornati G, Nesi M, Panzeri A: 17β-acylurea derivatives of 4-azasteroids as inhibitors of testosterone 5a-reductase. J Steroid Biochem Mol Biol 1992;41:765-768.
6. di Salle E, Giudici D, Briatico G, Ornati G, Panzeri A: Hormonal effects of turosteride, a 5α-reductase inhibitor, in the rat. J Steroid Biochem Mol Biol 1993;46:549-555.
7. Iehlé C, Délos S, Guirou O, Tate R, Raynaud JP, Martin PM: Human prostatic steroid 5 alpha-reductase isoforms - A comparative study of selective inhibitors. J Steroid Biochem Mol Biol 1995;54:273-279.
8. di Salle E, Briatico G, Giudici D, Ornati G, Panzeri A: Endocrine properties of the testosterone 5α-reductase inhibitor turosteride (FCE 26073). J Steroid Biochem Mol Biol 1994;48:241-248.
9. Zaccheo T, Giudici D, di Salle E: Effect of turosteride, a 5α-reductase inhibitor, on the Dunning R3327 rat prostatic carcinoma. Prostate 1997;30:85-91.
10. Geran RI, Greenberg NH, McDonald MM, Schumacher AM, Abbott BJ: Protocol for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother Rep 1972;3:1-103.
11. Vogelzang NJ, Kennealey GT: Recent developments in endocrine treatment of prostate cancer. Cancer 1992;70:966-976.
12. Hsieh W-S, Simons JW: Systemic therapy of prostate cancer. New concepts from prostate cancer tumor biology. Cancer Treat Rev 1993;19:229-260.
13. Metcalf BW, Levy MA, Holt DA: Inhibitors of steroid 5α-reductase in benign prostatic hyperplasia, male pattern baldness and acne. Trends Pharmacol Sci 1989;10:491-495.
14. Isaacs JT, Coffey DS: Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R3327-H adenocarcinoma. Cancer Res 1981;41:5070-5075.
15. Lamb JC, English H, Levandoski PL, Rhodes GR, Johnson RK, Isaacs JT: Prostatic involution in rats induced by a novel 5α-reductase inhibitor, SK&F 105657: Role for testosterone in the androgenic response. Endocrinology 1992;130:685-694.
16. Lamb JC, Levy MA, Johnson RK, Isaacs JT: Response of rat and human prostatic cancers to the novel 5α-reductase inhibitor, SKF 105657. Prostate 1992;21:15-34.
17. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, Andriole GL, Geller J, Brachen BR, Tenover JS, Vaughan ED, Pappas F, Taylor A, Binkowitz B, Ng J: The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992;327:1185-1191.
18. Stoner E: The clinical development of a 5α-reductase inhibitor, finasteride. J Steroid Biochem Mol Biol 1990;37:375-378.
19. Brooks JR, Berman C, Nguyen H, Prahalada S, Primka RL, Rasmusson GH, Slater EE: Effect of castration, DES, flutamide, and the 5α-reductase inhibitor, MK-906, on the growth of the Dunning rat prostatic carcinoma, R3327. Prostate 1991;18:215-227.
20. Ross RK, Bernstein L, Lobo RA, Shimizu H, Stanczyk FZ, Pike MC, Henderson BE: 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 1992;339:887-889.